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Abstract
Background: Supplementing mice with high levels of dietary n-3 polyunsaturated fatty acids
(PUFAs) increases the n-3 PUFAs in cell membranes, increases the susceptibility of the cells for lipid
peroxidation (LPO) and decreases the growth rate of mammary and other tumors. However, the
results of an earlier study indicated that a factor in addition to LPO was involved in the reduction
in tumor growth in n-3 PUFAs fed mice. Athymic mice bearing MDA-MB-231 human breast
carcinoma xenografts, were fed fish oil concentrate (FOC) or control diets, with and without
supplemental Vitamin E (2000 IU /kg diet) and were sacrificed both before and after doxorubicin
(DOX) treatment to evaluate factors involved in tumor growth suppression.
Results: Prior to DOX, basal LPO in the tumor of 3% FOC fed mice was slightly higher than in
the control fed mice and was decreased in mice consuming FOC with vitamin E. Vitamin E
suppressed the DOX induced increase in LPO in the tumors of control mice, however, vitamin E
was not sufficient to suppress a DOX induced increase in LPO in the tumors of FOC fed mice. The
mean growth rate of tumors of FOC fed mice was significantly less than the mean growth rate of
the tumors of control mice. Multiple regression analyses indicated that suppression of glutathione
peroxidase (GPX) activity by FOC prior to DOX therapy was more important than increased LPO
as an explanation of tumor growth suppression. Tumor induced cachexia was decreased in mice
consuming FOC.
Conclusions: It appears that the increased sensitivity to DOX was related to an FOC induced
reduction in GPX activity. FOC reduced tumor induced cachexia.

Background
The results of cell culture and animal studies have shown
that omega 3 polyunsaturated fatty acids (n-3 PUFAs) selectively killed cancer cells in vitro [1]. Furthermore, n-3
PUFAs incorporated into animal diets have reduced tumor growth rates in vivo [2–4]. The prevailing hypothesis
for the reduction in tumor cell growth, in vitro or in vivo,

by supplementing the diet with high levels of n-3 PUFAs
has been that the incorporation of n-3 PUFAs into cell
membranes of the tumor cells increased the susceptibility
of the cells for lipid peroxidation and that the products of
lipid peroxidation subsequently accumulated to cytostatic
or cytotoxic levels [2,5–7]. It has also been reported that
supplementing the diet of cancer xenograft bearing mice
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with n-3 PUFAs could increase the efficacy of edelfosine
[8], doxorubicin [9], mitomycin [10], cyclophosphomide
and 5-fluorouracil [11] or irinotecan [12] against the tumor. Since causing oxidative damage is one of the mechanisms of action of many of these drugs [13], the increased
efficacy of the drug has been attributed to increasing the
susceptibility of tumor cell membranes to lipid peroxidation.
However, the results of one of our early studies indicated
that some factor in addition to lipid peroxidation was involved in the reduction in xenograft growth in fish oil fed
mice [8]. A clue as to this factor(s) was found in the report
by Vankatraman et al. that antioxidant enzyme activity in
the liver was altered following long term consumption of
n-3 PUFAs [14]. We reasoned that alteration of antioxidant enzyme activity in the tumor by consumption of n-3
PUFAs prior to chemotherapy treatment could increase
oxidative stress within the tumor, perhaps resulting an enhanced sensitivity to oxidative stress induced by doxorubicin (DOX).
In this study, we wanted to test the hypothesis that there
are changes in the breast cancer xenografts of FOC fed
mice that sensitize the tumor to oxidative stress. MDA-MB
231 human breast cancer bearing athymic mice were fed
fish oil concentrate (FOC) or control diets, with and without supplemental vitamin E and were euthanized both before and after DOX treatment to test this hypothesis. DOX
was used to induce oxidative stress, supplemental vitamin
E was used to quench oxidative stress. An important aspect of the present study was that the n-3 PUFAs dietary
supplement be fed to mice at a level that humans could
readily consume. This level was based on calculation of
calories contributed by the oil as a fraction of the total caloric content of the diet. A product containing more than
65% omega 3 ethyl esters was used to increase the amount
of long chain n-3 PUFAs contained in a small quantity of
the n-3 PUFAs supplement. A high amount of a-tocopherol, (vitamin E, 2000 IU/kg diet) was added to the diet of
some mice to suppress lipid peroxidation in tissues.

Results
Fatty acid composition
The fatty acid compositions of the microsomal and mitochondrial membrane fractions of liver, colon and MDAMB 231 human breast tumor were analyzed by gas chromatography. The individual percent compositions for alinolenic, eicosapentaenoic and docosahexaenoic acids
were summed to estimate the fraction of n-3 fatty acids.
The individual percent compositions for linoleic and arachidonic acids were summed to estimate the fraction of n6 fatty acids. The ratios of the n-3 to n-6 fatty acids in each
tissue and subcellular fraction were subjected to statistical
analyses. A two way ANOVA revealed that the n-3 to n-6
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ratio (Table 1) was significantly higher in mice that consumed FOC than in mice that consumed corn oil (CO) indicating that n-3 fatty acids were incorporated in cellular
membranes when FOC was provided in the diet of the diet. Supplemental Vitamin E in the diet did not effect the
ratio of n-3 to n-6 fatty acids.
Antioxidant enzyme activity
To determine the effect of consumption of FOC on endogenous antioxidant enzyme activity, the activities of superoxide dismutase (SOD), catalase (CAT) and glutathione
peroxidase (GPX) were determined in the liver, colon and
tumor of mice that had consumed the diet for two weeks.
As summarized in Table 2, two way ANOVA revealed that
the activities of SOD, CAT and GPX were not significantly
altered in the liver or colon due to the consumption of
FOC or of supplemental Vitamin E for two weeks. However, GPX activity was significantly less in the tumors of
mice that consumed FOC than in the tumors of mice that
consumed CO and supplemental Vitamin E did not significantly alter GPX activity. Thus, the effect of consumption
of FOC on GPX activity was different in the tumor than in
the normal host liver or colon.
Lipid peroxidation
Lipid peroxidation was assayed in the livers, colons and
tumors of mice sacrificed after two weeks consumption of
each diet and after two weeks consumption of the diets
and a single injection of DOX 24 h before sacrifice (Table
3). Three way, two way and one way ANOVA revealed that
in the:
1) liver and colon
a) Lipid peroxidation was slightly suppressed by the addition of vitamin E to either diet, b) DOX treatment did not
significantly increase lipid peroxidation.
2) tumor
a) Supplemental vitamin E prevented an FOC induced increase in basal lipid peroxidation, b) supplemental vitamin E prevented the DOX induced increase in lipid
peroxidation in mice that consumed the corn oil diet but
did NOT prevent a DOX induced increase in lipid peroxidation in mice that consumed the FOC diet.
Tumor growth rates
Figure 1 illustrates the mean growth rates of the tumors of
each dietary group following DOX treatment. ANOVA revealed that the growth rates of the tumors of both groups
that consumed FOC were significantly less than the mean
growth rates of both of the groups of mice that consumed
either CO diet.
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Tumor growth after initiation of DOX
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Figure 1
Tumor growth after initiation of DOX treatment (see methods for dose and diets). Day 0 on the graph was the day of the first
DOX injection. The mean ± SE of the slope of each group (n = 4–8 per group) is indicated. One-way ANOVA followed by an
SNK multiple comparison test indicated that the slopes (tumor growth rates in mm3/day) of groups which do not share a
superscript were significantly (p < 0.05) different.

Table 1: The ratio of n-3 to n-6 fatty acids in the microsomal or mitochondrial membranes of liver, colon or tumor in mice fed a diet
containing either 5% corn oil (CO) or 3% fish oil concentrate (FOC) and 2% CO with or without 2000 IU/kg Vitamin E for two weeks.
Two way ANOVA revealed that consumption of supplemental Vitamin E did not effect the fatty acid composition thus ratios due to
dietary fat are shown. Mean ± SEM, (n).

Tissue

Fraction

5% CO

Liver

Microsomal
Mitochondrial
Microsomal
Mitochondrial
Microsomal
Mitochondrial

0.06
0.09
0.18
0.24
0.11
0.59

Colon
Tumor

a

± 0.02 (8)
± 0.02 (8)
± 0.09 (8)
± 0.09 (8)
± 0.10 (8)
± 0.57 (8)

3% FOC/2% COa

1.11 ± 0.18 (7)
0.77 ± 0.08 (7)
0.62 ± 0.15 (7)
0.59 ± 0.24 (7)
1.15 ± 0.10 (7)
1.32 ± 0.37 (7)

Fold difference

18.5
8.6
3.4
2.5
10.5
2.2

The n-3 to n-6 ratio was significantly higher in every tissue fraction of mice that consumed the FOC diet than in mice that consumed the CO diet.
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Table 2: Activities (mean + SE) of superoxide dismutase (SOD, units/mg protein), catalase (CAT, m mol H2O2decomposed/min/mg protein) and glutathione peroxidase (GPX, m mol b-NADP oxidized/g protein) in the tumors, livers and colon of groups of mice fed diets
containing either 5% CO or 3% FOC and 2% CO with or without 2000 IU Vitamin E/kg diet for two weeks.

Diet type

n

5% CO
5% CO + E
3% FOC
3% FOC + E

3
3
4
3

5% CO
5% CO + E
3% FOC
3% FOC + E

3
3
4
3

5% CO
5% CO + E
3% FOC
3% FOC + E

3
3
4
3

SOD

Tumor
10.0 ± 3.2
17.4 ± 7.2
9.0 ± 2.3
14.1 ± 1.9
Liver
214 ± 44
159 ± 16
156 ± 39
87 ± 10
Colon
4.8 ± 0.4
11.5 ± 1.5
2.2 ± 0.6
10.5 ± 3.6

GPX

CAT

131 ± 24a
118 ± 17a
60 ± 23a
13 ± 9b

20 ± 6
40 ± 17
28 ± 7
30 ± 10

358 ± 36
301 ± 65
308 ± 73
331 ± 96

531 ± 28
535± 12
579 ± 22
587 ± 67

325 ± 59
220 ± 38
172 ± 53
199 ± 42

28 ± 13
35 ± 14
21 ± 5
33 ± 9

a

One way ANOVA followed by an SNK multiple comparison test indicated that the mean GPX in the tumors of groups that share a superscript
were not significantly different (p < 0.05). There were no other significant differences.

Table 3: Thiobarbituric acid reactive substances (TBARS, nmols/mg protein, mean ± SE) in the tumors, livers and colons of groups of
mice fed diets containing either 5% CO or 3% FOC and 2% CO with or without 2000 IU Vitamin E/kg diet for two weeks. Some mice
were sacrificed 24 h after one injection of DOX (5 mg/kg body weight, i.v.).

Diet type

n

5% CO
5% CO + E
3% FOC
3% FOC + E

4
5
4
3

5% CO
5% CO + E
3% FOC
3% FOC + E

4
5
4
3

5% CO
5% CO + E
3% FOC
3% FOC + E

3
4
4
3

TBARS before DOX

Tumor
0.59 ± 0.30cd
0.53 ± 0.05cd
1.09 ± 0.14bc
0.38 ± 0.15d
Liver
1.09 ± 0.38b
0.69 ± 0.10b
1.77 ± 0.19a
0.61 ± 0.08b
Colon
2.58 ± 0.47a
2.10 ± 1.72a
3.40 ± 1.13a
2.27 ± 1.22a

n

TBARS after DOX

3
4
3
4

0.79 ± 0.12cd
0.59 ± 0.21cd
1.46 ± 0.29b
2.37 ± 0.37a

3
5
4
4

0.98 ± 0.06b
0.71 ± 0.09b
1.99 ± 0.31a
0.60 ± 0.08b

3
5
4
5

1.21 ± 0.57a
1.00 ± 0.48a
2.59 ± 1.01a
2.35 ± 0.77a

a,b,c,d One way ANOVA followed by an SNK multiple comparison test indicated that within each tissue type the mean TBARS of each group that
share a superscript were not significantly (p < 0.05) different.
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Table 4: Summary of forward multiple regression analyses between the measured independent variables: SOD, CAT and GPX activities
in the tumor and the TBARS in the tumor as measured after two weeks on the diet but before DOX treatment or as measured 24 h
after a single injection of DOX and the dependent variable, tumor growth rate during 5 weeks of DOC treatment.

Variable entered into equation

Intercept
GPX
TBARS after DOX

Parameter estimate

Partial R2 (Contribution each
variable)

Cumulative R2 (Cumulative contribution)

0.78
0.19

0.78
0.97

-17.3
0.138
6.50

Table 5: Mean body weight change g/wk ± SE (n) due to diet and to DOX treatment in mice bearing an MDA-MB-231 human breast
cancer xenograft.

Diet type

5% CO
5% CO + E
3% FOC
3% FOC + E
Results of 2-way ANOVA
Fat
Vit. E
Diet*Vit. E

Before DOX treatment Body weight change

After DOX treatment Body weight change

0.19 ± 0.15 (15)
0.11 ± 0.11 (17)
0.52 ± 0.06 (23)
0.33 ± 0.06 (22)

-0.42 ± 0.12 (6)
-0.32 ± 0.08 (8)
-0.32 ± 0.08 (6)
-0.40 ± 0.08 (4)

Sa
NS
NS

NS
NS
NS

a

The tumor bearing mice fed FOC gained significantly more body weight than tumor bearing mice fed CO before DOX treatment. There was no
significant difference in body weight loss due to diet in mice given DOX treatment for five weeks.

Multiple regression analyses
Values for the means of SOD, CAT, GPX activities and
TBARS from the tumors of groups of mice killed after two
weeks on each diet with or without DOX treatment and
the mean tumor growth rate of mice fed each diet and
treated with DOX for five weeks were entered into a forward multiple regression analyses. Multiple regression
analyses can address the question: What variable(s)
present in the tumor prior to or after DOX treatment best
correlates with the response of the tumor to DOX treatment? The results of the analyses (Table 4) revealed that
GPX activity in the tumor prior to DOX treatment explained 78% of the variation in tumor growth rate (the
correlation coefficient (r) between GPX activity in the tumor before DOX treatment and the tumor growth rate following DOX treatment was 0.88). Increased TBARS
following DOX treatment added an additional 19% explanation for the variation in tumor growth rate. Thus, 97%
of the variation in tumor growth rate could be explained
by the diet induced decrease in GPX activity and by increased lipid peroxidation in the tumor following DOX
treatment.

Body weight
The mean body weight change of each group of tumor
bearing mice following consumption of each diet for two
weeks or following DOX treatment for five weeks was determined. Two way ANOVA (Table 5) revealed that addition of Vitamin E to the diet did not significantly effect
body weight but that mice that consumed FOC prior to
DOX treatment gained significantly more weight than did
mice that consumed CO. Neither fat type nor Vitamin E
supplementation significantly altered the change in body
weight during five weeks of DOX treatment.

Discussion
The results of previous studies [2,5–8] indicated that peroxidation of highly polyunsaturated n-3 fatty acids, incorporated into cell membranes following their
consumption, was likely to be the primary mechanism for
tumor growth suppression following consumption of fish
oil. However, we recently reported that cellular oxidative
stress, as assayed by the ratio of glutathione peroxidase
(GPX) to superoxide dismutase (SOD) activity, was higher
in the MDA-MB 231 breast cancer xenograft of mice that
were fed 3% w/w FOC with 2% w/w corn oil prior to and
during 5 weeks of DOX treatment [15] than in the breast
Page 5 of 9
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cancer xenografts of mice that were fed 5% corn oil. If dietary antioxidants are constant, the antioxidative capacity
of tissues depends on the levels of protective cellular antioxidants [16]. Since endogenous antioxidative enzymes
can be altered by FOC consumption [14], we wondered if
oxidative stress was already increased in the MDA-MB 231
breast cancer xenograft of mice consuming FOC before
the initiation of DOX therapy, thereby increasing the sensitivity of the cancer xenograft to DOX.
The results of this study demonstrate that the implanted
MDA-MB 231 tumors of mice that consumed FOC were
more sensitive to DOX induced growth suppression and
exhibited more oxidative damage than the tumors of mice
that consumed the CO diets. Assay of antioxidant enzyme
activity in the tumors, prior to initiation of DOX therapy,
found that the GPX activity was already less in mice fed
FOC and significantly less in mice fed FOC + vitamin E
than in mice fed either CO diet. Reduced GPX activity
could be due: 1) to reduced transcription of GPX in the tumor 2) to 'using up' of the antioxidative capacity of GPX
or 3) to suppression of GPX activity by hydroperoxide
products of lipid peroxidation [17]. Further investigation
is needed to determine the precise reason but it is evident
that GPX activity was not maintained in tumor cells of
mice that consumed the FOC.
How could reduced GPX activity, associated with consumption of polyunsaturated fatty acids increase the sensitivity to oxidative stress? GPX has been described as the
most important enzyme for stabilizing oxidative reactions
in cells [17]. Under normal conditions, inhibition of GPX
is sufficient to alter cell survival [17] and low GPX activity
is especially lethal under conditions of oxidative stress
such as treatment with antineoplastic agents [17]. PUFAs
can undergo spontaneous and free radical-initiated chain
reactions of lipid peroxidation resulting in the formation
of reactive lipid hydroperoxides. Both GPX and CAT can
neutralize peroxides but GPX has been reported to be
more important than CAT to neutralize lipid hydroperoxides [18]. In cells with a high susceptibility for lipid peroxidation (i.e. tumor cells of FOC fed mice), adequate
GPX activity is essential to neutralize lipid hydroperoxides, breaking the chain reaction of peroxidative damage
and thus reducing the generation of free radicals. In the
current study and in our previous report [15], of the variables measured, the FOC induced decrease in GPX activity
in the tumor best explained the increased sensitivity of the
tumor to subsequent DOX chemotherapy. GPX was not
decreased in the normal colon or liver indicating that normal tissues responded to the FOC diet differently than did
the tumor and that normal tissues could maintain GPX activity.

http://www.cancerci.com/content/2/1/10

Body weight and tumor growth rate
It has been reported that omega 3 fatty acids can decrease
tumor cachexia [19–21]. It is important to note that tumor bearing mice that received only 3% FOC in their diet
gained more weight prior to initiation of DOX therapy
than mice that did not receive FOC. At the initiation of
DOX therapy, the tumors of FOC fed mice were slightly,
(but not significantly) smaller than the tumors of the CO
fed mice and at the end of the study the tumors of FOC fed
mice were significantly smaller than the tumors of CO fed
mice, thus the higher weight gain has to be body weight,
not tumor weight. The significantly higher body weight
gain is likely due to reduced tumor related cachexia.

CO and FOC fed groups did not lose different amounts of
body weight during DOX treatment. This fact and the
maintenance of antioxidant enzyme production in colon
and liver are indications that the toxicity of DOX to normal host tissues was not increased by the FOC diet.
The tumor growth curves (Figure 1) illustrate the significant enhancement of the efficacy of DOX against MDAMB 231 human breast cancer xenografts when FOC was
incorporated in the diet. The tumor growth rate of mice
consuming either FOC diet was significantly less than the
tumor growth rate of mice consuming either CO diet. It is
interesting that adding vitamin E to the CO diet slightly
increased the mean growth rate of the tumors. Since vitamin E quenches oxidation and oxidative damage is one of
the mechanisms of action of DOX [13], it would be expected that addition of vitamin E to the diet of mice bearing tumors with adequate GPX activity, might reduce the
efficacy of DOX against the tumor.

Conclusions
These results indicate that n-3 PUFAs in the diet are incorporated in cell membranes, increasing the polyunsaturation of the membrane and increasing the susceptibility for
lipid peroxidation. The inability of cancer cells to maintain the activity of GPX in the presence of a diet containing
n-3 PUFAs was related to increased oxidative damage to
membrane lipids and to significant enhancement of the
efficacy of DOX therapy. Tumor bearing mice that consumed n-3 PUFAs gained more weight prior to DOX therapy than mice that did not receive n-3 PUFAs indicating
that tumor induced cachexia was reduced. Clinical trials
are needed to test the use of this non-toxic supplement as
an adjuvant for patients undergoing DOX chemotherapy.

Methods and Materials
Preparation of cells
Cultured MDA-MB 231 cells (American Type Culture Collection, Rockville, MD) were harvested, rinsed then suspended in serum-free M3D base culture medium (INCELL
Corporation, LLC, San Antonio, TX). Cells in suspension
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Table 6: The energy content of the diet, calculated at 16.7 J/g for protein and carbohydrate, 37.7 J/g for fat is 16.3 J/g. Diet components
and chemicals – Purified high nitrogen casein, pure corn starch, Alphacel (non-nutritive bulk cellulose), AIN-76 vitamin mixture, AIN76 mineral mixture and choline bitartrate (99% pure) was obtained from ICN Nutritional Biochemicals, Cleveland, OH. Imperial brand
(Sugarland, TX) extra fine pure cane sugar and 100% pure corn oil (Wesson) were purchased locally. D.L. methionine was purchased
from Sigma, St. Louis, MO. Corn oil (CO) contains about 50% linoleic acid, 23% oleic acid, 10% C16 fatty acids and < 1% n-3 PUFAs. The
n-3 ethyl ester concentrate of fish oil (FOC) contains >65% n-3 ethyl esters, (>33% EPA, >22% DHA, 10% other n-3 fatty acids), was supplied antioxidant free by Lipromega AS, Norway.

Composition of the diet

Ingredient
Total fat
Sugar
Casein
Cornstarch
AIN-76 vitamin mix
AIN-76 mineral mix
Choline bitartrate
DL-methionine
Fiber

were counted using a hemocytometer and the cell count
was adjusted to 20 ´ 106/ml. The suspension was kept
well mixed during the time of injection. MDA-MB 231
cells (1 ´ 106 cells in 0.05 ml of serum free media) were
injected sc between the scapulae of each mouse.
Dietary fatty acids
Corn oil (CO) contains about 50% linoleic acid, 23%
oleic acid, 10% C16 fatty acids and < 1% n-3 PUFAs. The
n-3 ethyl ester concentrate of fish oil (FOC) containing >
65% n-3 ethyl esters, (> 33% EPA, > 22% DHA, 10% other
n-3 fatty acids), was obtained from the Lipro AS, Norway
and was supplied antioxidant-free. This oil is made in accordance with Good Manufacturing Practice and is approved as a food additive for humans. The oil is saturated
with nitrogen to prevent oxidation during shipping and
storage.
Animals and diet
This experiment was conducted at the University of Texas
Health Science Center. All animal use and handling was
approved by the UTHSCSA Institutional Animal Care and
Use Committee. Eighty female athymic nu/nu mice (Harlan Sprague Dawley Inc. Madison, WI), 3 months old received tumor cells. The mice were housed under aseptic
conditions in a temperature (24°C) and light-controlled
(12 h/day) room.

The tumor cell bearing mice were fed the AIN-76 semipurified diet from receipt until three weeks after injection of
cells to allow the tumor to become established. Nude
mice bearing growing MDA-MB-231 human breast carcinoma xenografts were then divided into four dietary

g/100 g
5.0
50.0
20.0
15.0
1.0
3.5
0.2
0.3
5.0

groups (20 mice per group) such that the mean tumor size
was not different between groups. One group received the
standard AIN-76 diet containing 5% CO (the CO diet),
one group received the 5% CO diet supplemented with
2000 IU/kg Vitamin E (the CO+E diet), one group, received the AIN-76 diet modified to contain 3% FOC and
2% CO (the FOC diet) and the final group received the
3% FOC and 2% CO supplemented with 2000 IU/kg Vitamin E (the FOC+E diet). Supplemental vitamin E was
added to quench in vivo lipid peroxidation due to the diet.
The diet composition is given in Table 6. Diets were prepared weekly, daily portions were individually packaged
and stored at -20°C in sealed containers with nitrogen gas
atmosphere to prevent lipid peroxidation. Mice were fed
fresh food each day and food remaining in the cage was
discarded.
Tumor and body weight measurements
Lengths and widths of tumors and body weights were
measured three times weekly. Tumor sizes were calculated
using the formula for the volume of a prolate spheroid: V
= 4/3 * 3.14 * L/2 * W/2 * D/2. The width measurement
was used as the depth of the tumor. The body weight
change before DOX treatment was determined by subtracting the mouse body weight on the day of the diet
change from the body weight on the day of the first DOX
treatment, thus this represents body weight change due to
effects of the growing tumor and of the diet. The body
weight change after DOX treatment was determined by
subtracting the mouse body weight on the day of the first
DOX injection from the mouse body weight on the day of
killing and represents body weight change due to diet, to
the growing tumor and to DOX therapy.
Page 7 of 9
(page number not for citation purposes)

Cancer Cell International 2002, 2

Doxorubicin therapy
After two weeks of consumption of the diets, five tumor
bearing mice from each dietary group were killed for assay
of the effects of the diet on the tumor and normal tissues
of the mice. DOX therapy (5 mg/kg body weight each 4
days, i.v. in a lateral tail vein) was initiated on the remaining mice of each group. Five tumor bearing mice from
each group were killed 24 h after one dose of DOX for determination of the acute effects of DOX on the sensitized
tumors and normal tissues. After two weeks of DOX treatment, mice were losing excess weight at the given schedule
of DOX treatment so the spacing of injections was increased to each seven days for the next three weeks and
mouse weight stabilized. The remainder of the mice (10
per diet group) received DOX treatment for a total of five
weeks to allow time to generate tumor growth curves and
to determine the long term effects of FOC consumption
and/or DOX treatment. Thus if day 0 was the day of the
first injection, mice received DOX injections on days 0, 4,
8, 12, 19, 26, and 33 and were sacrificed on day 1 or on
day 34.
Necropsy and tissue processing
Mice were deeply anesthetized using a ketamine/rompun
solution prepared by the UTHSCSA veterinarian. The tumor, liver and large intestines were removed at necropsy.
Portions of each tissue were placed individually in a labeled vial and flash frozen in liquid nitrogen. At a later
date, frozen livers, colon or tumor were thawed and homogenized individually at 4°C in 280 mM mannitol with
10 mM HEPES buffer with 0.01% BHT using a Polytron
homogenizer. The homogenate was divided into aliquots
and frozen at -70°C until subsequent analyses.
Products of lipid peroxidation in tumor, liver, and colon
The total protein content of an aliquot of each tissue homogenate was analyzed by the method of Bradford [22]
using the Bio-Rad protein assay (micro-method). The
thiobarbituric acid reactive substances (TBARS) assay was
used to estimate lipid peroxidation in the homogenate.
Malondialdehyde and other products of lipid peroxidation can be estimated spectrophotometrically at 535 nm
after reaction with thiobarbituric acid to obtain an index
for lipid peroxidation [23]. The absorbance values obtained were compared against a standard curve of known
concentrations of malondialdehyde and normalized to
the protein content of the specimen. The results were reported as nmol of TBARS per mg of protein.
Gas chromatography (GC)
The incorporation of fatty acids into the mitochondria
and microsomes of colon, liver and tumor was determined in mice which consumed each diet. An aliquot of
each whole tissue homogenate was fractioned into mitochondrial and microsomal fractions by successive centrif-
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ugation [600 ´ g for 10 min (remove large debris), 15,000
´ g for 5 min (mitochondrial fraction), then 100,000 ´ g
for 1 h (microsomal fraction)] for assay of lipid composition. Chloroform:methanol was used for lipid extraction
of each fraction; lipids were esterified in acetyl chloridemethanol as described [24]. Gas chromatography was
done using a Hewlett Packard 5890 Series 11 Gas Chromatograph (Palo Alto, CA) and conditions of: oven @
170°C initial, 5°/min gradient to 220°C final temperature,
injector temperature @ 225°C, flame-ionization detector
@ 250°C, helium carrier gas @ 400 Kpa. Fatty acid methyl
ester standards (Nu-Chek-Prep, Elysian, MN) were used
for peak identification. The fatty acid methyl esters were
reported as the percent of the total methylated fatty acids
(area under the curve).
Enzyme assays
Catalase (CAT) activity in the tissue homogenates was assayed using a microplate adaptation of the method of
Aebi [25]. In this method, the decomposition of H2O2
due to CAT activity was assayed by the decrease in the absorbance of H2O2 at 240 nm.

Superoxide dismutase (SOD) activity of tissue homogenates was determined using a microplate adaptation of
the ferricytochrome C reduction assay of Flohé and Ötting
[26]. In this method, the reduction of cytochrome C by superoxide radicals is monitored at 550 nm utilizing the
xanthine-xanthine oxidase system as the source for superoxide.
Glutathione peroxidase (GPX) activity of tissue homogenates was determined using a microplate adaptation of
the glutathione peroxidase assay of Paglia and Valentine
[27]. This method follows the decrease in absorbance at
340 nm as NADPH is converted to NADP.
Statistical analyses
SAS computer software was used for statistical analyses.
Tests for normality (basic statistics) were used on each
data set. Two-way and one-way analyses of variance
(ANOVA) followed by Student-Newman-Keuls (SNK)
multiple range tests, as appropriate, were used to determine statistically significant (p < 0.05) differences in
measured parameters due to the diet or to the chemotherapy. PRISM™ (GraphPad Software, San Diego, CA) was
used to generate an ANOVA to test for differences between
linear regression curves of tumor growth. Multiple linear
regression analysis with forward selection was used to test
for correlations in the data between the independent variables: SOD, CAT and GPX activity in the tumor prior to
DOX therapy, and TBARS prior to or after DOX therapy
and the dependent variable, the tumor growth rate following DOX treatment.

Page 8 of 9
(page number not for citation purposes)

Cancer Cell International 2002, 2

Acknowledgements

http://www.cancerci.com/content/2/1/10

21.

This work was supported by the Susan G. Komen Breast Cancer Foundation and by the American Institute for Cancer Research.

References
1.
2.

3.

4.
5.
6.
7.
8.

9.
10.
11.

12.

13.
14.

15.

16.

17.

18.
19.
20.

Begin ME, Ells G, Das UN, Horrobin DF: Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. J.Natl Cancer Inst. 1986, 77:1053-1062
Gonzalez MJ, Schemmel RA, Gray JI, Dugan LJ, Sheffield LG, Welsch
CW: Effect of dietary fat on growth of MCF-7 and MDAMB231 human breast carcinomas in athymic nude mice: Relationship between carcinoma growth and lipid peroxidation
product levels. Carcinogenesis 1991, 12:1231-1235
Rose DP, Connolly JM, Rayburn J, Coleman M: Influence of diets
containing eicosapentaenoic or docosahexaenoic acid on
growth and metastasis of breast cancer cells in nude mice. J
Natl Cancer Inst. 1995, 87:587-592
Gonzalez MJ, Schemmel RA, Dugan L, Gray JI, Welsch CW: Dietary
fish oil inhibits human breast carcinoma growth: a function
of increased lipid peroxidation. Lipids 1993, 28:827-832
Begin ME, Ells G, Horrobin DF: Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to
lipid peroxidation. J Natl Cancer Inst. 1988, 80:188-194
Das UN: Tumoricidal action of cis-unsaturated fatty acids and
their relationship to free radicals and lipid peroxidation. Cancer Lett 1991, 56:235-243
Gonzalez MJ: Fish oil, lipid peroxidation and mammary tumor
growth. J Am Coll Nutr. 1995, 14:325-335
Hardman WE, Barnes CJ, Knight CW, Cameron IL: Effects of iron
supplementation and ET-18-OCH 3 on MDA-MB 231 breast
carcinomas in nude mice consuming a fish oil diet. Br J Cancer
1997, 76:347-354
Hardman WE, Moyer MP, Cameron IL: Dietary fish oil sensitizes
A549 lung xenografts to doxorubicin chemotherapy. Cancer
Lett 2000, 151:145-151
Shao Y, Pardini L, Pardini RS: Dietary menhaden oil enhances mitomycin C antitumor activity toward human mammary carcinoma MX-1. Lipids 1995, 30:1035-1045
Shao Y, Hull J, Pardini L, Pardini RS: Dietary menhaden oil improves the therapeudic index of cyclophosphamide and 5fluorouracil towards MX-1 human mammary carcinoma in
athymic mice. Proc Am Assn Cancer Res: 1997, 38:110
Hardman WE, Moyer MP, Cameron IL: Fish oil supplementation
enhanced CPT-11 (Irinotecan) efficacy against MCF7 breast
carcinoma xenografts and ameliorated intestinal side effects. Br J Cancer 1999, 81:440-448
Dorr RT, Von Hoff DD: Cancer Chemotherapy Handbook (Edited by: Dorr RT, Von Hoff DD) Connecticut: Appleton & Lange 1994
Vankatraman JT, Chandrasekar B, Kim JD, Fernandes G: Effects of n3 and n-6 fatty acids on the activities and expression of hepatic antioxidant enzymes in autoimmune-prone NZB ´
NZW F1 mice. Lipids 1994, 29:561-568
Hardman WE, Avula CPR, Fernandes G, Cameron IL: Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts. Clin
Cancer Res. 2001, 7:2041-2049
Das UN: Tuning free radical metabolism to kill tumor cells selectively with emphasis on the interaction(s) between essential fatty acids, free radicals, lymphokines and
prostaglandins. Indian J Pathol Microbiol. 1990, 33:94-111
Remacle J, Lambert D, Raes M, Pigeolet E, Michiels C: Importance
of various antioxidant enzymes for cell stability: Confrontation between theoretical and experimental data. Biochem J
1992, 286:41-46
Fernandes G, Chandrasekar B, Luan X, Troyer DA: Modulation of
antioxidant enzymes and programmed cell death by n-3 fatty acids. Lipids 1996, 31:S91-S96
Tisdale MJ, Dhesi JK: Inhibition of weight loss by omega-3 fatty
acids in an experimental cachexia model. Cancer Res 1990,
50:5022-5026
Tisdale MJ: The effects of eicosapentaenoic acid on tumour
growth and cachexia in the MAC16 mouse colon cancer
model. In: New approaches to cancer treatment: Unsaturated lipids and
photodynamic therapy. (Edited by: Horrobin DF) London: Churchill Livingston 1995, 30-39

22.
23.
24.
25.
26.
27.

Wigmore SJ, Ross JA, Falconer JS, Plester CE, Tisdale MJ, Carter DC,
Fearon KCH: The effect of polyunsaturated fatty acids on the
progress of cachexia in patients with pancreatic cancer. Nutrition 1996, 12:S27-S30
Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254
Esterbauer H, Zollner H: Methods for determination of aldehydic lipid peroxidation products. Free Rad Biol Med 1989, 7:197203
Ackman RG: Simplification of analyses of fatty acid in fish lipids
and related lipid samples. Acta Med Scand 1987, 222:99-103
Aebi H: Catalase in vitro. Methods Enzymol 1984, 105:121-125
Flohe L, Otting F: Superoxide dismutase assays. Methods Enzymol
1984, 105:93-104
Paglia DE, Valentine WN: Studies on quantitative and qualitative characterization of erythrocyte glutathione peroxidase.
J Lab Clin Med 1967, 70:158-169

Publish with BioMed Central and every
scientist can read your work free of charge
"BioMedcentral will be the most significant development for
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central
yours - you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/

BioMedcentral.com
editorial@biomedcentral.com

Page 9 of 9
(page number not for citation purposes)

